News
CAI
23.40
+2.90%
0.66
Weekly Report: what happened at CAI last week (0803-0807)?
Weekly Report · 16h ago
Caris Life Sciences (CAI) Stock Price Jumps As Profitability Meets Valuation Doubts
Simply Wall St · 3d ago
Caris Life Sciences Price Target Raised to $33.00/Share From $32.00 by BTIG
Dow Jones · 3d ago
Caris Life Sciences Is Maintained at Buy by BTIG
Dow Jones · 3d ago
Caris Life Sciences: Guidance Raised, Valuation Still Attractive
Seeking Alpha · 3d ago
Analysts Are Bullish on These NA Stocks: Harrow Health (HROW), Caris Life Sciences, Inc. (CAI)
TipRanks · 4d ago
Caris Life Sciences Price Target Raised to $26.00/Share From $25.00 by Evercore ISI Group
Dow Jones · 4d ago
Caris Life Sciences Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 4d ago
Caris Life Sciences Up Over 15%, on Pace for Record Percent Increase -- Data Talk
Dow Jones · 4d ago
Evercore ISI Group Maintains Outperform on Caris Life Sciences, Raises Price Target to $26
Benzinga · 4d ago
Caris Life Sciences price target raised to $26 from $25 at Evercore ISI
TipRanks · 4d ago
Piper Sandler Keeps Their Hold Rating on Caris Life Sciences, Inc. (CAI)
TipRanks · 4d ago
Caris Life Sciences, Inc. (CAI) Receives a Hold from Canaccord Genuity
TipRanks · 4d ago
Caris Life Sciences, Inc. GAAP EPS of $0.00 misses by $0.01, revenue of $263.7M beats by $25.62M
Seeking Alpha · 5d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 5d ago
Caris Life Sciences reports Q2 EPS 0c, consensus 1c
TipRanks · 5d ago
Caris Life Sciences sees 2026 revenue $1.03B-$1.04B, consensus $”This was a reco
TipRanks · 5d ago
Caris Life Sciences Raises FY2026 Sales Guidance from $1.000B-$1.020B to $1.030B-$1.040B vs $1.003B Est
Benzinga · 5d ago
*Caris Life Sciences 2Q Rev $263.7M >CAI
Dow Jones · 5d ago
*Caris Life Sciences 2Q EPS 0c >CAI
Dow Jones · 5d ago
More
Webull provides a variety of real-time CAI stock news. You can receive the latest news about Caris Life Sciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.